Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos NYSE:GKOS said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years after a single treatment for keratoconus, a disease that can progressively distort vision.